Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma: A multicenter phase II study

Cancer

Volumn 92, Issue 9, 2001, Pages 2435-2443

  Calvo, Emiliano ^a,f   Cortés, Javier ^a   Rodríguez, Javier ^a   Sureda, Manuel ^b   Beltrán, César ^c   Rebollo, Joseba ^d   Martínez Monge, Rafael ^a   Berián, José María ^a   De Irala, Jokin ^e   Brugarolas, Antonio ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b HOSPITAL GENERAL DE CATALUNYA   (Spain)

^c Clinica Salvia   (Spain)

^d Clinica San Miguel   (Spain)

^e UNIVERSITY OF NAVARRA   (Spain)

^f USP Hospital San Jaime   (Spain)

Author keywords

Hormone refractory; Phase II study; Prostate carcinoma; Prostate specific antigen (PSA); Suramin

Indexed keywords

HYDROCORTISONE; PROSTATE SPECIFIC ANTIGEN; SURAMIN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROCORTISONE; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PAIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURAMIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035498519     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20011101)92:9<2435::AID-CNCR1593>3.0.CO;2-O     Document Type: Article

References (48)

1. Prostate cancer: Screening, diagnosis, and management
2. Leuprolide versus diethylstilbestrol for metastatic prostate cancer
3. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
4. Treatment and survival of patients with cancer of the prostate
5. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer
6. Chemotherapy in advanced prostate cancer
7. Suramin binds to platelet-derived growth factor and inhibits its biological activity
8. Suramin: Pharmacology and antitumor effectiveness of an old parasiticide
9. Transformation of NIH 3T3 cells with basic fibroblast growth factor or the hst/K-fgf oncogene causes downregulation of the fibroblast growth factor receptor: Reversal of morphological transformation and restoration of receptor number by Suramin
10. Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells
11. Observations on the Suramin-mediated inhibition of cellular and viral DNA polymerases
12. Suramin and hydrocortisone: Determining drug efficacy in androgen-independent prostate cancer
13. Antitumor activity of Suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables
14. Phase I study of Suramin given by intermittent infusion without adaptive control in patients with advanced cancer
15. Phase I and clinical evaluation of a pharmacologically guided regimen of Suramin in patients with hormone-refractory prostate cancer
16. Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer
17. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer
18. Suramin: An anticancer drug with a unique mechanism of action
19. Suramin, an active drug for prostate cancer: Interim observations in a phase I trial
20. Development and validation of a pharmacokinetically based fixed dosing scheme for Suramin
21. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing Suramin plus hydrocortisone to placebo plus hydrocortisone
22. Suramin (SUR) is safe and active in prostate cancer without adaptive control: Evidence for dose-response
23. Phase I/II trial of Suramin (SUR) in hormone-refractory prostate cancer (HRPC): Evidence of antitumor activity over a broad range of plasma SUR concentrations
24. Suramin and function of the adrenal cortex
25. Effects of Suramin on the function and structure of the adrenal cortex in the cynomolgus monkey
26. Bioanalysis of Suramin in human plasma by ion-pair high-performance liquid chromatography
27. Field-testing of the WHO guidelines for cancer pain relief: Summary report of demonstration projects
28. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group
29. Non-parametric estimation from incomplete observations
30. Evaluation of survival data and two new rank order statistics arising in its consideration
31. Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of Suramin
32. A phase I/II study of continuous infusion Suramin in hormone-refractory prostate cancer: Toxicity and response rate
33. Prognostic factors in stage D2 prostate cancer: Important implications for future trials: Results of a cooperative intergroup study (INT.0036)
34. A critical assessment of the role of chemotherapy for endocrine-resistant prostatic carcinoma
35. Phase I study of Suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer
36. Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response
37. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study
38. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
39. The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: An analysis of cancer and leukemia group B study 9181 of megestrol acetate
40. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
41. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer
42. Suramin in hormone-refractory metastatic prostate cancer: A drug with limited efficacy
43. Prospective evaluation of hydrocortisone and Suramin in patients with androgen-independent prostate cancer
44. Phase II trial of Suramin in patients with metastatic renal cell carcinoma
45. Androgen deprivation and four courses of fixed-schedule Suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study
46. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer
47. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer